دورية أكاديمية

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study

التفاصيل البيبلوغرافية
العنوان: CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
المؤلفون: David S. Moura, Paloma Sanchez-Bustos, Antonio Fernandez-Serra, María Lopez-Alvarez, José L. Mondaza-Hernandez, Elena Blanco-Alcaina, Angela Gavilan-Naranjo, Paula Martinez-Delgado, Serena Lacerenza, Paloma Santos-Fernandez, Irene Carrasco-Garcia, Samuel Hidalgo-Rios, Antonio Gutierrez, Rafael Ramos, Nadia Hindi, Miguel Taron, Jose Antonio Lopez-Guerrero, Javier Martin-Broto
المصدر: Cancers; Volume 12; Issue 5; Pages: 1128
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2020
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: trabectedin, ERCC1, CUL4A, predictive biomarkers, soft-tissue sarcoma
الوصف: A translational study was designed to analyze the expression of nucleotide excision repair (NER) and homologous recombination (HR) genes as potential predictive biomarkers for trabectedin in soft-tissue sarcoma (STS). This study is part of a randomized phase II trial comparing trabectedin plus doxorubicin versus doxorubicin in advanced STS. Gene expression levels were evaluated by qRT-PCR, while CUL4A protein levels were quantified by immunohistochemistry. Expression levels were correlated with patients’ progression-free survival (PFS) and overall survival (OS). Gene expression was also evaluated in cell lines and correlated with trabectedin sensitivity. In doxorubicin arm and in the whole series, which includes samples from both arms, no significant differences in terms of PFS were observed amongst the analyzed genes. In the group treated with trabectedin plus doxorubicin, the median of PFS was significantly longer in cases with CUL4A, ERCC1, or ERCC5 overexpression, while BRCA1 expression did not correlated with PFS. Gene expression had no prognostic influence in OS. CUL4A protein levels correlated with worse PFS in doxorubicin arm and in the whole series. In cell lines, only overexpression of ERCC1 was significantly correlated with trabectedin sensitivity. In conclusion, CUL4A, ERCC5, and mainly ERCC1 acted as predictive factors for trabectedin efficacy in advanced STS.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
العلاقة: https://dx.doi.org/10.3390/cancers12051128Test
DOI: 10.3390/cancers12051128
الإتاحة: https://doi.org/10.3390/cancers12051128Test
حقوق: https://creativecommons.org/licenses/by/4.0Test/
رقم الانضمام: edsbas.5330AE5
قاعدة البيانات: BASE